Tristan Manalac is a contributing writer at BioSpace. With over eight years of experience, he specializes in medicine, healthcare, and alternative medicine, drawing on his formal training in molecular biology to inform his writing. Tristan's work often explores topics such as the FDA, Coronavirus, and legal affairs within the medical field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Tristan Manalac's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly FDA approvals, drug development, and related market movements. His reliance on press releases and data citations suggests a preference for fact-based reporting.
Given his focus on specific companies and regulatory developments in the pharmaceutical industry, Tristan is likely to be responsive to pitches from experts with direct knowledge of relevant drugs, therapies or regulatory processes. Additionally, he may be interested in insights into market trends impacting drug pricing or innovative approaches in drug development.
While geographic focus isn't specified, considering that pharma news often has global implications due to multinational companies involved in research and distribution of drugs worldwide would also be important when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025.
By: Tristan, Manalac
After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals' gastroparesis drug candidate tradipitant.
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
By: Tristan Manalac
The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to significant improvements in progression-free survival, calling it the “major efficacy outcome” of the trial.
By: Tristan, Manalac
Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare negotiations or not. The CMS has until June 1 to send an initial offer for the adjusted prices.
By: Tristan Manalac
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
The FDA is putting Atara's active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx's investigational ALS therapy from a previous pause.
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.
By: Tristan, Manalac
Spravato's monotherapy nod on Tuesday comes after a series of setbacks in the depression space.
By: Tristan, Manalac
With an eye toward advancing a novel antibody-drug conjugate for gastrointestinal cancers, ArriVent is the latest biopharma player to ink a deal with a Chinese biotech.
(833) 317-6278 
